Cyclacel Pharmaceuticals Expands Operations with Acquisition of Fitters Sdn. Bhd.

Introduction

CYCLACEL PHARMACEUTICALS INC (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company headquartered in Berkeley Heights, New Jersey, with additional operations in Dundee, Scotland. Established in 1996, the company develops oral therapies targeting oncology and hematology indications based on its research in cell cycle biology, transcriptional regulation, and epigenetics. On July 15, 2025, the stock closed at $4.68, reflecting a 41.39 percent increase on a volume of 1,772,680 shares. The company is also listed under the ticker CYCCP for its public warrants and preferred share units. In Korean markets, it is known as 사이클라셀 파머슈티컬스.

Corporate Structure

Cyclacel operates with a team of 11 to 50 employees and retains full global rights to its proprietary pipeline. The executive leadership is headed by President & CEO Spiro Rombotis, supported by a board experienced in tumor suppressor biology and mitosis research. Since its founding by Sir David Lane and David Glover in collaboration with the Universities of Dundee and Glasgow, Cyclacel has utilized academic insights alongside private equity and public markets to fund its research and development initiatives.

Biopharmaceuticals by little plant

Recent Developments and News

On May 6, 2025, Cyclacel entered into a Share Exchange Agreement to acquire Fitters Sdn. Bhd., a Malaysian company specializing in fire safety materials and waste-to-resource services. Under the agreement, Cyclacel will issue common stock equivalent to 19.99 percent of its outstanding shares to Fitters’ parent, Fitters Diversified Berhad, establishing Fitters Sdn. Bhd. as a wholly-owned subsidiary. This transaction is pending shareholder approvals, after which the combined entity is expected to trade under a new ticker and be renamed Bio Green Med Solution, Inc.

On July 7, 2025, Cyclacel filed a DEF 14C with the SEC, disclosing the private placement of 3 million shares of Series F Convertible Preferred Stock at $1.00 per share, generating $3 million in gross proceeds and issuing 29.43 million warrants. Proceeds are designated for general corporate and operating purposes. The filing included a 4.99 percent conversion limit per holder without further approval.

In its Phase 2 study of fadraciclib (formerly CYC065), Cyclacel completed enrollment of a biomarker-enriched cohort targeting patients with CDKN2A/CDKN2B abnormalities. Data regarding efficacy and safety will be presented at the European Neuro-Oncology Association (ENA) Symposium in October 2024.

At the 26th Annual H.C. Wainwright & Co. Global Investment Conference, scheduled for September 9–11, 2024, Spiro Rombotis will deliver a corporate presentation, which will be accessible on-demand starting September 9 at 7 AM ET.

Financial and Strategic Analysis

Cyclacel’s share price increase on July 15 reflects market response to the Fitters transaction and the company’s capital-raising efforts. The DEF 14C filing supports its cash position ahead of upcoming Phase 2 milestones. Conversion limits on the Series F Preferred Stock are intended to mitigate dilution risks but may necessitate future approvals if individual holdings exceed 4.99 percent.

The strategic acquisition of Fitters expands Cyclacel’s operations into industrial safety and resource management, diversifying revenue streams beyond biopharmaceuticals. This transaction is contingent upon closing conditions by August 31, 2025, and aims to enhance growth and shareholder value through cross-industry integration.

Market Position and Industry Context

Within the oncology market, Cyclacel operates in the sector of cell cycle-targeted oral therapies. Its two lead programs, fadraciclib (a CDK2/9 inhibitor) and plogosertib (a PLK1 inhibitor), are developed to treat solid tumors and hematological malignancies, which are recognized as areas with high unmet medical need. As a small-cap company on the Nasdaq Capital Market, Cyclacel is positioned among emerging growth biotechnology firms, balancing the advancement of its pipeline with capital efficiency. Competitors range from global pharmaceutical companies conducting extensive oncology trials to specialized biotech firms focusing on targeted therapies.

tl;dr

Cyclacel agreed on May 6, 2025, to acquire Malaysia’s Fitters Sdn. Bhd. in a share exchange that will issue 19.99 percent of its stock to Fitters’ parent, pending approvals and renaming to Bio Green Med Solution. On July 7, the company raised $3 million through Series F Preferred Stock and issued 29.43 million warrants. Enrollment concluded in a biomarker-defined Phase 2 cohort of fadraciclib, with data to be presented at the ENA Symposium in October 2024. The share price increased 41.39 percent to $4.68 on July 15, connected to investor response to the acquisition and financing ahead of forthcoming clinical readouts.